Education
About Us
Working with TipRanks
Follow Us
Purple Biotech Ltd. (IL:PPBT)
:PPBT
Total Valuation
Purple Biotech has a market cap or net worth of 22.30M. The enterprise value is 3.00M.
Market Cap22.30M
Enterprise Value3.00M
Share Statistics
Purple Biotech has 1,858,479,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,858,479,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Purple Biotech’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -33.11%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-33.11%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee0.00
Profits Per Employee-808.78K
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Purple Biotech is ―. Purple Biotech’s PEG ratio is -0.00056.
PE Ratio―
PS Ratio0.00
PB Ratio0.32
Price to Fair Value0.32
Price to FCF-0.73
Price to Operating Cash Flow-0.25
PEG Ratio-0.00056
Income Statement
In the last 12 months, Purple Biotech had revenue of 0.00 and earned -7.24M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-62.00K
Operating Income-11.01M
Pretax Income-7.28M
Net Income-7.24M
EBITDA-7.05M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -6.54M and capital expenditures 1.01M, giving a free cash flow of -5.54M billion.
Operating Cash Flow-6.54M
Free Cash Flow-5.54M
Free Cash Flow per Share>-0.01
Dividends & Yields
Purple Biotech pays an annual dividend of 249.549, resulting in a dividend yield of ―
Dividend Per Share249.549
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change-80.95%
50-Day Moving Average1.22
200-Day Moving Average3.33
Relative Strength Index (RSI)46.52
Average Volume (3m)8.90M
Important Dates
Purple Biotech upcoming earnings date is Feb 11, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateFeb 11, 2026
Ex-Dividend Date―
Financial Position
Purple Biotech as a current ratio of 2.23, with Debt / Equity ratio of 0.32%
Current Ratio2.23
Quick Ratio2.23
Debt to Market Cap0.00
Net Debt to EBITDA1.02
Interest Coverage Ratio-268.41
Taxes
In the past 12 months, Purple Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Purple Biotech EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.23.
EV to Sales0.00
EV to EBITDA-0.47
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23
Balance Sheet
Purple Biotech has 10.45M in cash and marketable securities with 256.00K in debt, giving a net cash position of 10.20M billion.
Cash & Marketable Securities10.45M
Total Debt256.00K
Net Cash10.20M
Net Cash Per Share<0.01
Tangible Book Value Per Share<0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Purple Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast89.32%